- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03271736
Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease
Study Overview
Status
Conditions
Detailed Description
Parkinson's disease is a common neurodegenerative disease and movement disorder. Due to the degeneration of basal ganglia, patients with Parkinson's disease also demonstrate internal rhythm dysfunction, thus will lead to difficulty in rhythmic movements such as ambulation. For improving the rhythmic movement problem, auditory cues are often used in clinical setting and shows benefits in ambulation and freezing problems. Previous studies often use finger tapping test and ambulation to assess the rhythmic movement problem. No study uses stepping in place movements as a test to examine rhythmic problem. Little study investigates the effects of auditory cues on brain cortical excitability. In this cross-over study, participants will receive 2 times of training include stepping-in-place exercise with and without auditory cues in random orders. Auditory cues are given via the metronome. There is one-week wash-out period between two trainings. Movement tests such as walking and stepping-in-place and transcranial magnetic stimulation (TMS) are carried out before and after each training.
The investigators hypothesize the variation of rhythmic movements such as walking and stepping-in-place will be reduced more, and the cortical excitability would be modulated after the training with auditory cues, comparing with the other training without auditory cues.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Department of physical therapy, National Taiwan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
[Patients with Parkinson's disease]
Inclusion Criteria:
- Diagnosed with idiopathic Parkinson's disease
- No hearing impairment
- Able to walk independently for at least 10m
- Able to follow command (MMSE >=24)
[Healthy subjects]
- No hearing impairment
- Able to walk independently for at least 10m
- Able to follow command (MMSE >=24)
Exclusion Criteria:
- With other neurological diseases or psychological diseases
- Dementia
- Family history of epilepsy
- History of head trauma, surgery, or metal implants
- Having pacemaker or other electrical stimulators
- History of syncopes or frequent migraines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Freezer
All the subjects received 2 experiments.
2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments.
The difference between 2 experiments is the application of auditory cues.
One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues).
Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
|
The stepping-in-place exercise includes 10-session training.
In each session, subjects are asked for stepping for 50 steps.
In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence.
While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
Other Names:
TMS is used to assess the cortical excitability of the motor cortex.
The stimulation intensity is set at 130% of the motor threshold in single-pulse condition.
In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
|
EXPERIMENTAL: Non-freezer
All the subjects received 2 experiments.
2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments.
The difference between 2 experiments is the application of auditory cues.
One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues).
Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
|
The stepping-in-place exercise includes 10-session training.
In each session, subjects are asked for stepping for 50 steps.
In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence.
While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
Other Names:
TMS is used to assess the cortical excitability of the motor cortex.
The stimulation intensity is set at 130% of the motor threshold in single-pulse condition.
In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of transcranial magnetic stimulation (TMS) parameters
Time Frame: TMS parameters are assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Single-pulse and paired-pulse TMS are used to measure the cortical excitability of the motor cortex and the integrity of the intracortical inhibitory/facilitatory circuits.
The TMS parameters include motor threshold (MT), motor evoke potential, silent period, short intracortical inhibition and facilitation.
In single-pulse condition, the stimulation intensity is set at 130% of the MT.
While in the paired-pulse condition, the first conditioning stimulus is set at 80% of MT, the second test stimulus is set at 130% of MT.
|
TMS parameters are assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variation of walking step time
Time Frame: The step time variability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Subjects are asked to walk on a GAITRite carpet under usual walking speed.
Duration between each step can be recorded through the system.
|
The step time variability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Walking ability
Time Frame: The walking ability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Walking speed, stride length and cadence are recorded as secondary outcome measures.
Subjects are asked to walk on a GAITRite carpet under usual walking speed.
|
The walking ability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Variation of stepping-in-place movement
Time Frame: The step variability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Subjects are asked to stand and do stepping-in-place movement on a force plate.We use force plate to detect the vertical force and calculate the variation of each step.
|
The step variability is assessed immediately before and after a 30-minute intervention. The data will be reported through study completion, for average of 6 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jau Yih Tsauo, PT, phD, department of physical therapy, college of medicine, National Taiwan University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201609085RINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain